問卷

TPIDB > Principal Investigator

Principal Investigator


Hsinchu Mackay Memorial Hospital (在職)

Division of Dermatology

MacKay Memorial Hospital (在職)

Division of Dermatology

MacKay Memorial Hospital

Division of Dermatology

更新時間:2023-09-19

吳南霖
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

21Cases

2020-10-09 - 2020-12-10

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated7Sites

2023-01-27 - 2025-09-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting2Sites

Terminated2Sites

2024-01-01 - 2027-05-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2024-12-01 - 2027-11-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2025-01-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2028-04-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-02-01 - 2025-08-05

Completed
A multinational, multicenter, double-blind, placebo-controlled phase 2 trial evaluating the efficacy and safety of SAR444656 in adult subjects with moderate to severe atopic dermatitis.
  • Condition/Disease

    The study aimed to evaluate the efficacy of SAR444656 compared to placebo in treating AD lesions in adult subjects with moderate to severe AD. • Percentage change in EASI from baseline to week 16.

  • Test Drug

    SAR444656

Participate Sites
4Sites

Recruiting4Sites

2018-10-01 - 2020-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2024-09-01 - 2031-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3